Trinean Secures 1 Million Euro Financing
News May 29, 2013
Trinean announced to have secured a 1 million euro investment in a second closing of its 3.7 million fundraising round. The investment is done by Capricorn Health-tech Fund NV (Leuven, Belgium) which is managed by Capricorn Venture Partners NV.
Dr. Gaston Matthyssens, Trinean’s president, comments on today’s announcement: “Over the past 24 months, Trinean has proven to be able to attract substantial funding to boost its market and sales strategy, and to bring novel, state-of-the-art instruments to the market. Most recently, we have launched the Xpose®, our new micro-volume spectrophotometer for high speed quantification of nucleic acid or proteins samples”.
Dr. Frank Bulens, Partner at Capricorn Venture Partners, will join Trinean’s board of directors. “We are very pleased to enforce the existing investor syndicate of Trinean and are looking forward to assist the company in reaching its next phase of development, namely to become a successful player in the micro-volume spectroscopy market,” comments Frank Bulens, “In our view Trinean will achieve that goal based on a superior product offering supported by a seasoned management team.”
“We are delighted to welcome Capricorn Health-tech Fund to our investor syndicate,” says Philippe Stas, CEO Trinean, “This will allow Trinean to accelerate its applicationdriven expansion of the DropSense96® and Xpose® product lines and to extend our production facilities, matching the increasing demand for instruments and microfluidic solutions.”
Compact Chemical Sensor Can Detect Substances from Over 100 Feet AwayNews
A chemical sensor prototype developed at the University of Michigan will be able to detect "single-fingerprint quantities" of substances from a distance of more than 100 feet away, and its developers are working to shrink it to the size of a shoe box. The development offers great potential for medical and law enforcement purposes.READ MORE
Multidisciplinary Study Suggests New Strategy for Drug DiscoveryNews
A joint industry/academia study of a cancer target protein reveals unusual relation between binding site flexibility and drug-target lifetime. The results, , suggest a new strategy for drug discovery.READ MORE